AMRX files 8-K for $1.8B term loan, $750M secured notes offering

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K announcing a two-part debt refinancing initiative. Its operating subsidiary is marketing $1.8 billion of new seven-year term loan B debt and has launched a private offering of $750 million senior secured notes due 2032. Net proceeds are earmarked to (i) refinance the company’s existing term B loans in full, (ii) repay a portion of borrowings under the ABL facility, and (iii) cover related fees and expenses.

The notes will be issued under Rule 144A/Reg S and will not be registered with the SEC. Completion, size and terms of both transactions remain subject to market conditions; the notes offering is not contingent on closing of the new term loan facility. No financial results or forward guidance were provided.

Key takeaways for investors:

• Potentially extends weighted-average debt maturity to 2032.
• Transaction could restructure up to $2.55 billion of the capital stack.
• Execution risk exists because neither transaction is assured.

Positive

• Refinancing could extend debt maturities, reducing near-term refinancing risk.
• Partial repayment of ABL facility may increase revolver availability and liquidity headroom.

Negative

• Transaction size is large ($2.55 bn), keeping leverage elevated.
• Execution is not guaranteed; adverse market conditions could delay or alter terms.

Insights

Debt Capital Markets Analyst

TL;DR – Large refinancing may improve maturity profile but adds issuance risk.

The proposed $1.8 bn TLB and $750 mn secured notes would fully refinance existing TLB borrowings and trim ABL balances, maintaining secured leverage but likely extending duration seven years (TLB) and to 2032 (notes). Because both instruments are secured, overall borrowing costs may stay near current levels despite a higher rate backdrop. Investor impact hinges on pricing and demand; tight spreads could be viewed favorably, while wide spreads would signal credit concern. Lack of contingency between tranches gives flexibility but also market-timing risk. Near term, the disclosure is neutral: no committed funding, no covenant changes, and no guidance on interest expense.

false 0001723128 0001723128 2025-07-21 2025-07-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 21, 2025

AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38485		93-4225266
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

400 Crossing Blvd

Bridgewater, NJ 08807

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (908) 947-3120

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.01 per share		AMRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On July 21, 2025, Amneal Pharmaceuticals, Inc. (the “Company”) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking to borrow $1,800 million of new seven-year term B loans (the “new term B loans”) under a new term loan facility and has launched an offering of $750 million aggregate principal amount of senior secured notes due 2032 (the “notes”) in a private offering. The Issuer intends to use the net proceeds of the new term B loans and the notes to refinance its existing term B loans in full, to repay a portion of outstanding amounts borrowed under its ABL facility and to pay related fees, premiums and expenses.

The offering of the notes is not conditioned on entry into the new term loan facility. Further, the proposed transactions are subject to market conditions and other factors, and there can be no assurance as to whether or when these transactions may be completed, or as to the actual size or terms of the transactions.

The notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act. The offering of notes will be made only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act and to non-U.S. persons in accordance with Regulation S under the Securities Act. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Neither this Current Report on Form 8-K nor the press release attached hereto as Exhibit 99.1 constitutes an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are furnished herewith:

Exhibit No.		Description
99.1		Press release issued July 21, 2025.
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 21, 2025				AMNEAL PHARMACEUTICALS, INC.
				By:		/s/ Anastasios Konidaris
				Name:		Anastasios Konidaris
				Title:		Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

FAQ

What did Amneal Pharmaceuticals (AMRX) announce in its July 21 2025 8-K?

A plan to raise $1.8 bn in 7-year term loan B debt and $750 mn in senior secured notes due 2032 to refinance existing debt.

How will AMRX use the proceeds from the new debt?

To refinance its current term B loans entirely, repay part of the ABL facility, and pay fees and expenses.

Are the new notes registered with the SEC?

No. The notes will be offered privately under Rule 144A/Reg S and are not registered under the Securities Act.

Is completion of the notes offering contingent on the new term loan?

No. The notes offering can close independently of the term loan facility.

What risks did the company highlight?

The deals depend on market conditions, and there is no assurance on timing, size, or final terms.